CAL
IMRX icon

Capital Advisors Ltd’s Immuneering IMRX Stock Holding History

Capital Advisors Ltd’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39
Closed – – 1488
2024
Q2 		$0 Buy
+39
New +$64 ﹤0.01% 1507

Other funds holding IMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Capital Advisors Ltd's IMRX Position: Q3 2024 in Review

Capital Advisors Ltd sold out of Immuneering (IMRX) in Q3 2024, closing a stake of 39 shares.

Capital Advisors Ltd first reported a position in IMRX in Q2 2024 and held it in 1 quarter. The position peaked at $0 in Q2 2024. 38 funds tracked by Wall St. Rank hold IMRX as of Q3 2024.

  • Capital Advisors Ltd reported no remaining Immuneering position as of Q3 2024 after selling out during the quarter.
  • Capital Advisors Ltd sold 39 Immuneering shares in Q3 2024.
  • Capital Advisors Ltd first reported a position in Immuneering in Q2 2024 and held it in 1 quarter.
  • Capital Advisors Ltd's Immuneering position peaked at $0 in Q2 2024.
  • 38 funds tracked by Wall St. Rank held Immuneering as of Q3 2024.

Based on Capital Advisors Ltd's 13F filing for Q3 2024, filed 24 Oct 2024.